{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:21:19Z","timestamp":1788891679820,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.abd.2025.501253","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:08:18Z","timestamp":1767859698000},"page":"501253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of meglumine antimoniate versus miltefosine in the treatment of new world cutaneous leishmaniasis: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8714-2962","authenticated-orcid":false,"given":"Ana Carolina Putini","family":"Vieira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Cronemberger","family":"Lins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianne Costa","family":"Baqui\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2025.501253_bib0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5021\/ad.2013.25.1.80","article-title":"New world cutaneous leishmaniasis treated with intralesional injection of pentavalent antimony","volume":"25","author":"Shin","year":"2013","journal-title":"Ann Dermatol."},{"key":"10.1016\/j.abd.2025.501253_bib0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/tmi.13210","article-title":"American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment","volume":"24","author":"Carvalho","year":"2019","journal-title":"Trop Med Int Health."},{"key":"10.1016\/j.abd.2025.501253_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012323","article-title":"American cutaneous leishmaniasis: imported cases in Berlin 2000-2023","volume":"18","author":"Lindner","year":"2024","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.abd.2025.501253_bib0020","unstructured":"paho.org. Cutaneous and mucosal leishmaniasis - PAHO\/WHO Pan american health organization [Internet]. Pan American Health Organization. Available from: https:\/\/www.paho.org\/en\/topics\/leishmaniasis\/cutaneous-and-mucosal-leishmaniasis."},{"key":"10.1016\/j.abd.2025.501253_bib0025","series-title":"In: CDC yellow book 2024: health information for international travel [Internet]","article-title":"Leishmaniasis","year":"2024"},{"key":"10.1016\/j.abd.2025.501253_bib0030","unstructured":"World Health Organization [Internet]. c2023-2025 [cited 2025 Apr 27]. Leishmaniasis; [about 5 screens]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis."},{"key":"10.1016\/j.abd.2025.501253_bib0035","first-page":"653","article-title":"Global leishmaniasis surveillance updates 2023: 3 years of the NTD road map","volume":"45","author":"Jain","year":"2024","journal-title":"World Health Organ"},{"key":"10.1016\/j.abd.2025.501253_bib0040","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1086\/518041","article-title":"Influence of leishmania (viannia) species on the response to antimonial treatment in patients with american tegumentary leishmaniasis","volume":"195","author":"Arevalo","year":"2007","journal-title":"J Infect Dis."},{"key":"10.1016\/j.abd.2025.501253_bib0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1590\/S0365-05962007000200002","article-title":"Treatment of American cutaneous leishmaniasis","volume":"82","author":"Lima","year":"2007","journal-title":"An Bras Dermatol."},{"key":"10.1016\/j.abd.2025.501253_bib0050","series-title":"Miltefosina para o tratamento da leishmaniose tegumentar [Internet]","year":"2018"},{"key":"10.1016\/j.abd.2025.501253_bib0055","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/0974-777X.62887","article-title":"Drug resistance in leishmaniasis","volume":"2","author":"Chakravarty","year":"2010","journal-title":"J Glob Infect Dis."},{"key":"10.1016\/j.abd.2025.501253_bib0060","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.actatropica.2018.03.016","article-title":"Liposomal amphotericin B treatment of old world cutaneous and mucosal leishmaniasis: a literature review","volume":"182","author":"Mosimann","year":"2018","journal-title":"Acta Trop."},{"key":"10.1016\/j.abd.2025.501253_bib0065","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/tropicalmed8090430","article-title":"Systematic review of treatment failure and clinical relapses in leishmaniasis from a multifactorial perspective: clinical aspects, factors associated with the parasite and host","volume":"8","author":"Almeida-Santos","year":"2023","journal-title":"Trop Med Infect Dis."},{"key":"10.1016\/j.abd.2025.501253_bib0070","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2019011","article-title":"Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis","volume":"41","author":"Iranpour","year":"2019","journal-title":"Epidemiol Health."},{"key":"10.1016\/j.abd.2025.501253_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061843","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update","volume":"8","author":"Reveiz","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.abd.2025.501253_bib0080","article-title":"Interventions for american cutaneous and mucocutaneous leishmaniasis","volume":"8","author":"Pinart","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.abd.2025.501253_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2021.105944","article-title":"Comparative assessment of interventions for treating cutaneous leishmaniasis: a network meta-analysis of randomized clinical trials","volume":"220","author":"Sridharan","year":"2021","journal-title":"Acta Trop."},{"key":"10.1016\/j.abd.2025.501253_bib0090","series-title":"Cochrane handbook for systematic reviews of interventions version 6.5. Cochrane","author":"Higgins","year":"2024"},{"key":"10.1016\/j.abd.2025.501253_bib0095","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.abd.2025.501253_bib0100","article-title":"RoB 2: a revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"10.1016\/j.abd.2025.501253_bib0105","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/jep.13016","article-title":"The evolution of GRADE (part 3): a framework built on science or faith?","volume":"24","author":"Mercuri","year":"2018","journal-title":"J Eval Clin Pract."},{"key":"10.1016\/j.abd.2025.501253_bib0110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4269\/ajtmh.2011.10-0155","article-title":"Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by leishmania (viannia) guyanensis in Manaus, Brazil","volume":"84","author":"Chrusciak-Talhari","year":"2011","journal-title":"Am J Trop Med Hyg."},{"key":"10.1016\/j.abd.2025.501253_bib0115","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1371\/journal.pntd.0000912","article-title":"Miltefosine in the treatment of cutaneous leishmaniasis caused by leishmania braziliensis in Brazil: a randomized and controlled trial","volume":"4","author":"Machado","year":"2010","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.abd.2025.501253_bib0120","doi-asserted-by":"crossref","first-page":"e2465","DOI":"10.1093\/cid\/ciaa1337","article-title":"A double-blind, randomized trial to evaluate miltefosine and topical granulocyte macrophage colony-stimulating factor in the treatment of cutaneous leishmaniasis caused by leishmania braziliensis in Brazil","volume":"73","author":"Machado","year":"2021","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.abd.2025.501253_bib0125","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijid.2020.11.183","article-title":"Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the amazon region: a randomized and controlled trial","volume":"103","author":"Mendes","year":"2021","journal-title":"Int J Infect Dis."},{"key":"10.1016\/j.abd.2025.501253_bib0130","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jir816","article-title":"Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children","volume":"205","author":"Rubiano","year":"2012","journal-title":"J Infect Dis."},{"key":"10.1016\/j.abd.2025.501253_bib0135","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4269\/ajtmh.2008.78.210","article-title":"Efficacy of miltefosine for bolivian cutaneous leishmaniasis","volume":"78","author":"Soto","year":"2008","journal-title":"Am J Trop Med Hyg."},{"key":"10.1016\/j.abd.2025.501253_bib0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1473-3099(06)70665-X","article-title":"Oral miltefosine to treat new world cutaneous leishmaniasis","volume":"7","author":"Soto","year":"2007","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.abd.2025.501253_bib0145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4269\/ajtmh.2010.10-0060","article-title":"Efficacy of miltefosine for the treatment of american cutaneous leishmaniasis","volume":"83","author":"V\u00e9lez","year":"2010","journal-title":"Am J Trop Med Hyg."},{"key":"10.1016\/j.abd.2025.501253_bib0150","unstructured":"World Health Organization [Internet]. Geneva: WHO. c1992-2025 [cited 2024 Dec 27]. Miltefosine \u2013 WHO expert committee on selection and use of essential medicines; [about 3 screens]. Available from: https:\/\/list.essentialmeds.org\/recommendations\/781."},{"key":"10.1016\/j.abd.2025.501253_bib0155","unstructured":"Paladin Therapeutics, Inc. IMPAVIDO (miltefosine) [label on the Internet]. Wilmington (DE): Paladin Therapeutics. c2014. [cited 2024 Nov 19]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204684s000lbl.pdf."},{"key":"10.1016\/j.abd.2025.501253_bib0160","unstructured":"Aventis Pharma Ltd. Glucantime: summary of product characteristics [Internet]. Haverhill (UK): Aventis Pharma; [date unknown] [cited 2024 Nov 30]. Available from: https:\/\/www.astmh.org\/getmedia\/35e1061e-82f7-4fc2-b05b-e3845e5aad8f\/Glucantime-Drug-Profile.pdf."},{"key":"10.1016\/j.abd.2025.501253_bib0165","doi-asserted-by":"crossref","first-page":"e2130","DOI":"10.1371\/journal.pntd.0002130","article-title":"Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis","volume":"7","author":"Olliaro","year":"2013","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.abd.2025.501253_bib0170","unstructured":"WHO Expert Committee on the Control of the Leishmaniases, World Health Organization. Control of the leishmaniases: report of a meeting of the WHO expert commitee on the control of leishmaniases, Geneva, 22-26 march 2010 [Internet]. 2010 [cited 2024 Nov 24]. Available from: https:\/\/iris.who.int\/handle\/10665\/44412."},{"key":"10.1016\/j.abd.2025.501253_bib0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009460","article-title":"Miltefosine for the treatment of cutaneous leishmaniasis-a pilot study from ethiopia","volume":"15","author":"van Henten","year":"2021","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.abd.2025.501253_bib0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005515","article-title":"Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: a cohort study","volume":"11","author":"Castro","year":"2017","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.abd.2025.501253_bib0185","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","article-title":"Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the new world","volume":"118","author":"Oliveira","year":"2011","journal-title":"Acta Trop."},{"key":"10.1016\/j.abd.2025.501253_bib0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005459","article-title":"Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver dot for the treatment of pediatric cutaneous leishmaniasis","volume":"11","author":"Berger","year":"2017","journal-title":"PLoS Negl Trop Dis."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625001953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625001953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:19:41Z","timestamp":1771604381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059625001953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0365059625001953"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2025.501253","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of meglumine antimoniate versus miltefosine in the treatment of new world cutaneous leishmaniasis: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2025.501253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501253"}}